Why Is Twist Bioscience (TWST) Stock Up +7.79% Today?
Key Takeaways
- TWST shares rose about 7.79% to roughly $203.37, building on a prior close of $188.67.
- The move pushed the stock to a fresh 52-week high, extending a powerful multi-month rally.
- Primary driver: sustained momentum around AI-driven drug discovery, anchored by partnerships with Eli Lilly and Anthropic.
- Secondary support: a series of bullish analyst price-target increases and sector enthusiasm for genomics-plus-AI names.
- Traders are watching upcoming fiscal fourth-quarter results and the company's path to adjusted EBITDA breakeven.
Opening Summary
Twist Bioscience Corporation (TWST), a South San Francisco-based synthetic biology company that manufactures synthetic DNA, genes, oligos, and antibody discovery services, surged in Monday's session. The stock advanced roughly 7.79% to about $203.37, up from a prior close of $188.67, touching a new 52-week high along the way. The rally reflected continued investor enthusiasm for the company's growing role as infrastructure for AI-enabled drug discovery, rather than any single fresh headline.
AI Drug Discovery Momentum
The clearest catalyst behind the move is Twist Bioscience's deepening integration with the AI-driven drug discovery ecosystem. In September, the company announced it would provide antibody characterization data and services to LLY's TuneLab AI/ML drug discovery platform, feeding laboratory results directly into model training. That announcement followed August research involving Anthropic in which Twist's laboratory work helped validate AI-designed proteins. Investors increasingly view Twist as a "picks-and-shovels" supplier to the AI biology theme — a company selling the synthetic DNA and wet-lab validation that AI models need to design and test therapeutic candidates at scale.
Analyst Support and Target Increases
The share-price rally has also been reinforced by a wave of Wall Street optimism. Guggenheim more than doubled its price target to $212 from $107, while Leerink Partners raised its target in stages, most recently to $190, citing early adoption of AI-driven drug discovery. TD Cowen and Baird also lifted targets following the company's third-quarter update. These upgrades reflect a view that the Street had been underestimating pharma and biotech adoption of Twist's platform.
Fundamental Backdrop
The stock's strength is not purely sentiment-driven. Twist reported fiscal third-quarter revenue of $118.4 million, up 23% year over year, with DNA synthesis and protein services growing 39% and therapeutic revenue rising 49%. Gross margin improved to 52.8%, and management raised its full-year revenue outlook to a range of $456 million to $457 million while reiterating a goal of adjusted EBITDA breakeven in the fiscal fourth quarter. Management has also signaled confidence in another year of triple-digit percentage order growth in AI-enabled drug discovery.
Market Context and Trading Activity
The advance aligned with a broader re-rating of genomics and life-science tools names tied to the AI-biology convergence. Twist is a top holding in the ARK Genomic Revolution ETF (ARKG), underscoring institutional positioning around the theme. The stock's move to a new 52-week high also carried technical significance, clearing prior resistance and leaving the shares well above their 50-day and 200-day moving averages. Still, the rally has attracted skepticism: the company remains unprofitable on a GAAP basis, trades at a lofty price-to-sales multiple, and has seen notable insider selling, including by CEO Emily Leproust, as the stock has climbed.
What Comes Next for TWST
Investor focus now turns to Twist's fiscal fourth-quarter results and, critically, its ability to deliver on adjusted EBITDA breakeven. Management has said it intends to provide full fiscal 2027 guidance in November, and the market will scrutinize whether AI-enabled drug discovery orders continue to scale and whether margin gains persist. Key risks include continued GAAP losses, customer concentration in next-generation sequencing, execution around new product launches, and the possibility that a richly valued stock faces sharper drawdowns if growth disappoints. Insider selling and stretched valuation metrics remain areas of caution even as momentum persists.
Trending AI Robots
For traders seeking a systematic approach to fast-moving names like TWST, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a way to explore automated approaches aligned with today's market environment. Explore the Trending AI Robots to see which strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TWST turns positive, indicating new upward trend
TWST saw its Momentum Indicator move above the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In 68 of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TWST just turned positive on September 17, 2026. Looking at past instances where TWST's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +7.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 233 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 182 of 227 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.738) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement